Virginia Powers, PhD | Authors


Acalabrutinib Shows High Response, Prolonged Survival in Ibrutinib-Intolerant R/R CLL

September 24, 2019

Bruton tyrosine kinase inhibitor acalabrutinib demonstrated a high rate of response, prolonged survival, and high tolerability in patients with chronic lymphocytic leukemia who demonstrated intolerance to ibrutinib. Findings were presented at the 15th International Conference on Malignant Lymphoma.

Genetic Analysis Provides Insight Into Venetoclax/Obinutuzumab Benefit in Frontline CLL

September 18, 2019

Rate of response and progression-free survival were superior with venetoclax versus chlorambucil in patients with chronic lymphocytic leukemia who also received obinutuzumab, and this trend was observed across all genetic subgroups.

Frontline Treatment With Lenalidomide Plus R-CHOP May Benefit Select Patients With DLBCL

June 27, 2019

Lenalidomide plus standard R-CHOP immunochemotherapy may help select patients with activated B-cell-type diffuse large B-cell lymphoma who have a poor prognosis, based on data from the phase III ROBUST trial presented at the 2019 International Conference on Malignant Lymphoma.

High Response Rate Seen With Concurrent Ibrutinib Plus CAR T-Cell Therapy in High-Risk CLL

June 26, 2019

Significant activity was observed when ibrutinib was administered concurrently with CD19-directed CAR T-cell therapy compared with separately in patients with high-risk relapsed/refractory chronic lymphocytic leukemia who had progressed on or were intolerant of ibrutinib. Data presented at the 15th International Conference on Malignant Lymphoma show a high response rate with this concurrent treatment.

Relapsed/Refractory PMBCL Shows High Response Rate to Nivolumab and Brentuximab Vedotin

June 24, 2019

A combination of nivolumab plus brentuximab vedotin was highly active in 73% of patients with relapsed/refractory primary mediastinal large B-cell lymphoma, based on results from the phase I/II CheckMate 436 trial, recently announced during the 15th International Conference on Malignant Lymphoma.

Concerning Mortality Increase Seen With Venetoclax/Bortezomib Combo in Phase III Trial

June 21, 2019

The combination of venetoclax and bortezomib lead to an increased number of deaths by infection in patients with multiple myeloma in the phase III BELLINI trial, according to data presented at the 2019 EHA Congress. Deaths increased in spite of promising responses data and a high progression-free survival rate.